TY - JOUR
T1 - Fasciitis and myositis
T2 - An analysis of muscle-related complications caused by chronic GVHD after allo-SCT
AU - Oda, K.
AU - Nakaseko, C.
AU - Ozawa, S.
AU - Nishimura, M.
AU - Saito, Y.
AU - Yoshiba, F.
AU - Yamashita, T.
AU - Fujita, H.
AU - Takasaki, H.
AU - Kanamori, H.
AU - Maruta, A.
AU - Sakamaki, H.
AU - Okamoto, S.
PY - 2009
Y1 - 2009
N2 - The muscle-related complications of fasciitis and myositis, caused by chronic GVHD after Allo-SCT are relatively rare, but at times will severely impair a patient's quality of life (QOL). We performed a retrospective analysis in Japanese Allo-SCT recipients to identify the incidence, risk factors and clinical features of fasciitis and myositis. In 1967 patients who underwent Allo-SCT between January 1994 and March 2005 and survived beyond 90 days post transplantation, eight patients developed fasciitis and nine patients developed myositis, with a 5-year cumulative incidence of 0.55% and 0.54%, respectively. The median time from SCT to the development of fasciitis and myositis was 991 and 660 days, respectively. PBSCT was a risk factor for developing fasciitis, but no risk factors were found for myositis. The response to immunosuppressive treatment was better in patients with myositis than fasciitis, and the overall survival after developing these symptoms was better in patients with myositis than those with fasciitis. An early diagnosis by a biopsy, which includes fascia and muscle or magnetic resonance imaging (MRI) and prompt treatment may be important to prevent an impairment of the patient's QOL with persistent disability.
AB - The muscle-related complications of fasciitis and myositis, caused by chronic GVHD after Allo-SCT are relatively rare, but at times will severely impair a patient's quality of life (QOL). We performed a retrospective analysis in Japanese Allo-SCT recipients to identify the incidence, risk factors and clinical features of fasciitis and myositis. In 1967 patients who underwent Allo-SCT between January 1994 and March 2005 and survived beyond 90 days post transplantation, eight patients developed fasciitis and nine patients developed myositis, with a 5-year cumulative incidence of 0.55% and 0.54%, respectively. The median time from SCT to the development of fasciitis and myositis was 991 and 660 days, respectively. PBSCT was a risk factor for developing fasciitis, but no risk factors were found for myositis. The response to immunosuppressive treatment was better in patients with myositis than fasciitis, and the overall survival after developing these symptoms was better in patients with myositis than those with fasciitis. An early diagnosis by a biopsy, which includes fascia and muscle or magnetic resonance imaging (MRI) and prompt treatment may be important to prevent an impairment of the patient's QOL with persistent disability.
UR - http://www.scopus.com/inward/record.url?scp=59549083592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59549083592&partnerID=8YFLogxK
U2 - 10.1038/bmt.2008.297
DO - 10.1038/bmt.2008.297
M3 - Article
C2 - 18762758
AN - SCOPUS:59549083592
SN - 0268-3369
VL - 43
SP - 159
EP - 167
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 2
ER -